公开(公告)号：US20090131455A1

公开(公告)日：2009-05-21

申请号：US12269306

申请日：2008-11-12

申请人： Michael Gerard Gallagher ,  Craig C. Jamieson ,  Amanda Jane Lyons ,  John Kinnaird Ferguson Maclean ,  Elizabeth Margaret Moir

发明人： Michael Gerard Gallagher ,  Craig C. Jamieson ,  Amanda Jane Lyons ,  John Kinnaird Ferguson Maclean ,  Elizabeth Margaret Moir

IPC分类号： A61K31/519 ,  C07D495/04

CPC分类号： C07D495/04

摘要： The present invention relates to a heterocyclic derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and learning and memory disorders such as Alzheimer's disease.

摘要翻译： 本发明涉及式I的杂环衍生物，其中变量如说明书中所定义，或其药学上可接受的盐或溶剂合物。 本发明还涉及包含所述杂环衍生物的药物组合物及其在治疗中的用途，例如用于治疗或预防精神疾病，其中需要由AMPA受体介导的突触应答的增强，包括精神分裂症，抑郁和学习，以及 记忆障碍如阿尔茨海默病。

公开(公告)号：US08129397B2

公开(公告)日：2012-03-06

申请号：US12269306

申请日：2008-11-12

申请人： Michael Gerard Gallagher ,  Craig C. Jamieson ,  Amanda Jane Lyons ,  John Kinnaird Ferguson Maclean ,  Elizabeth Margaret Moir

发明人： Michael Gerard Gallagher ,  Craig C. Jamieson ,  Amanda Jane Lyons ,  John Kinnaird Ferguson Maclean ,  Elizabeth Margaret Moir

IPC分类号： C07D495/04 ,  A61K31/519 ,  A61P25/24 ,  A61P25/28 ,  A61P25/22 ,  A61P25/18 ,  A61P25/16

CPC分类号： C07D495/04

摘要： The present invention relates to a heterocyclic derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and learning and memory disorders such as Alzheimer's disease.

摘要翻译： 本发明涉及式I的杂环衍生物，其中变量如说明书中所定义，或其药学上可接受的盐或溶剂合物。 本发明还涉及包含所述杂环衍生物的药物组合物及其在治疗中的用途，例如用于治疗或预防精神疾病，其中需要由AMPA受体介导的突触应答的增强，包括精神分裂症，抑郁和学习，以及 记忆障碍如阿尔茨海默病。